Quarterly ResultJul 27, 2026, 04:38 PM
GeoVax Q2 Net Loss $4.43M; Advances GEO-MVA & Gedeptin Programs
AI Summary
GeoVax Labs, Inc. reported a net loss of $4.43 million, or $0.97 per share, for the second quarter of 2026, an improvement from a $5.37 million loss in the prior year. Revenue for the quarter was $0, following the termination of its BARDA contract in April 2025. The company continued to advance its GEO-MVA pivotal immunobridging study, with planned initiation in Q4 2026, and its Gedeptin® immuno-oncology program, while strategically discontinuing its GEO-CM04S1 COVID-19 vaccine candidate development.
Key Highlights
- Reported Q2 2026 net loss of $4.43 million, or $0.97 per share.
- Q2 2026 revenue was $0, down from $852,282 in Q2 2025 due to BARDA contract termination.
- Research and development expenses decreased to $3.11 million in Q2 2026 from $4.73 million in Q2 2025.
- General and administrative expenses decreased to $1.33 million in Q2 2026 from $1.54 million in Q2 2025.
- Cash balances remained stable at approximately $3.1 million as of June 30, 2026.
- Common shares outstanding increased to 7,369,243 as of June 30, 2026, from 1,732,147 at Dec 31, 2025.
Price Impact
More from GOVX